Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evolution in Strategies for Getting FDA Approvals

Executive Summary

Pharma must adjust rapidly to a new regulatory world dominated by FDA’s new drug safety authority. Post-marketing risk management plans are likely to be the key to surviving in the new climate. But beware: they change the relationship of pharma companies to doctors and patients. And they also drastically change the nature of pre-approval filings to FDA.

You may also be interested in...



Pyramid Schemes and Pipeline Dreams: Adapting to a Tiered Regulatory System for New Drugs

FDA's new drug safety authorities suggest that the focus of drug development and lifecycle management strategies need to change. It is no longer a question of what it takes to get approval from FDA, but rather what kind of approval you can get.

A New Phase for Phase IV: Post-marketing Studies Won't Be the Same After Drug Safety Bill

The world of post-approval research is going to get more public, more crowded, and more dangerous to pharma. Post-marketing surveillance, transparent clinical trial results and mandated post-approval studies mean the traditional world of marketing-oriented Phase IV is about to change dramatically.

Playing Doctor: The Impact of the Tysabri Risk Plan

The market resurrection of Tysabri demonstrates the power of risk management but raises a tough question: how far can FDA and industry go into the practice of medicine? Biogen Idec declare they are nt trying to tell doctors how to practice. The strict rules of the risk management plan suggest otherwise.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002862

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel